Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Cage Rattler who wrote (1344)	10/29/1998 11:55:00 AM
From: tommysdad	Read Replies (1) \| Respond to of 2135

PNAS: I just went to website for the National Academy of Sciences (found via a Yahoo search) and a couple of clicks later was looking at the PNAS site. I'm on a network (not at home) and I have subsequently discovered that we have subscribed to the web version -- I didn't have to sign in or anything. Sorry for the confusion. Ignorance is bliss. The text of the article describes exactly what you have stated -- CM101 was "able to inhibit the inflammatory angiogenesis and scarring event, which otherwise would prevent recovery of connectivity" in vitro. In vivo, CM101 "caused the observed inhibition of gliosis, which facilitated axonal reconnection and subsequent recovery of function". They're not claiming healing of spinal cords, simply allowing the body to heal itself by inhibiting an inflammatory effect. They clearly are planning clinical trials of this agent in spinal cord injury patients. As another poster noted, let's hope thalidomide, AS/ES, and AG3340 are tested soon.